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Abstract
Phosphatidylserine (PS) was exposed at the surface of human umbilical vein endothelial cells (HUVECs) and cultured cell
lines by agonists that increase cytosolic Ca2, and factors governing the adhesion of T cells to the treated cells were
investigated. Thrombin, ionophore A23187 and the Ca2-ATPase inhibitor 2,5-di-tert-butyl-1,4-benzohydroquinone each
induced a PS-dependent adhesion of Jurkat T cells. A23187, which was the most effective agonist in releasing PS-bearing
microvesicles, was the least effective in inducing the PS-dependent adhesion of Jurkat cells. Treatment of ECV304 and
EA.hy926 cells with EGTA, followed by a return to normal medium, resulted in an influx of Ca2 and an increase in
adhering Jurkat cells. Oxidised low-density lipoprotein induced a procoagulant response in cultured ECV304 cells and
increased the number of adhering Jurkat cells, but adhesion was not inhibited by pretreating ECV304 cells with annexin V.
PS was not significantly exposed on untreated Jurkat cells, as determined by flow cytometry with annexin V^FITC. However,
after adhesion to thrombin-treated ECV304 cells for 10 min followed by detachment in 1 mM EDTA, there was a marked
exposure of PS on the Jurkat cells. Binding of annexin V^FITC to the detached cells was inhibited by pretreating them with
unlabelled annexin V. Contact with thrombin-treated ECV304 cells thus induced the exposure of PS on Jurkat cells and, as
Jurkat cells were unable to adhere to thrombin-treated ECV304 cells in the presence of EGTA, the adhesion of the two cell
types may involve a Ca2 bridge between PS on both cell surfaces. The number of T cells from normal, human peripheral
blood that adhered to ECV304 cells was not increased by treating the latter with thrombin. However, findings made with
several T cell lines were generally, but not completely, consistent with the possibility that adhesion to surface PS on
endothelial cells may be a feature of T cells that express both CD4 and CD8 antigens. Possible implications for PS-
dependent adhesion of T cells to endothelial cells in metastasis, and early in atherogenesis, are discussed. ß 2000 Elsevier
Science B.V. All rights reserved.
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1. Introduction
An energy-dependent aminophospholipid translo-
case [1] is present in the plasma membranes of most
cells, including endothelial cells [2], which transports
the anionic phospholipid, phosphatidylserine (PS),
from the outer to the inner lea£et of the phospholip-
id bilayer. Consequently, PS is normally found only
in the inner lea£et of the plasma membrane [3^5] but,
following the activation of scramblase activity by an
increase in cytosolic Ca2, it rapidly appears on the
cell surface [6^8] where it can mediate cell^cell inter-
actions [9^11]. Since there is accumulating evidence
for the importance of interactions between T cells
and endothelial cells in the development and progres-
sion of atherosclerosis [12^14], we have characterised
the adhesive response of Jurkat T cells to endothelial
cell lines that have been treated with several agonists,
including oxidised low-density lipoprotein (LDL),
that increase cytosolic Ca2 and expose PS at the
cell surface. Experiments have also been undertaken
on the mechanism of Jurkat cell adhesion to agonist-
treated endothelial cells. Contact with thrombin-
treated ECV304 cells was found to induce the expo-
sure of PS on Jurkat cells and, since the adhesion of
Jurkat cells was also Ca2-dependent, a Ca2 bridge
between PS on the surface of both cell types may be
involved in their interaction. Other experiments with
peripheral blood T cells and with a number of T cell
lines provided some, but not conclusive, evidence for
the possibility that adhesion to surface PS on endo-
thelial cells may be a feature of double-positive
CD4/CD8 T cells.
2. Materials and methods
2.1. Materials
Factor II (prothrombin), thrombin, factor Xa, gel-
atin, hematoxylin (Gill’s No. 1), Histopaque 1077
and diaminobenzidine tetrahydrochloride (DAB)
were from Sigma (Poole, Dorset, UK). Factor V
was from Diagnostic Reagents Ltd. (Thame, Oxon,
UK). Chromogenic substrate S-2238 (H-D-phenyl-
alanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydro-
chloride) was from Chromogenix AB (Mo«lndal, Swe-
den). 5-Chloromethyl£uorescein diacetate (CMFDA)
and £uo-3-acetoxymethyl ester (£uo-3 AM) were
from Molecular Probes Europe BV (Leiden, The
Netherlands). Ionophore A23187 free acid, 2,5-di-
tert-butyl-1,4-benzohydroquinone (BHQ), 4-bromo-
A23187 and TNF-K were from Calbiochem^Nova-
biochem (Nottingham, UK). Recombinant annexin
V, annexin V^FITC and propidium iodide (PI)
were from Pharmingen (Cowley, Oxford, UK). An-
nexin V was puri¢ed to homogeneity (Mr = 33 000)
from chicken liver [15]: the protein (1100 nM) com-
pletely abolished the prothrombinase activity of son-
icated vesicles of PS (0.25 WM) (not shown). Culture
medium 199 with or without phenol red, RPMI 1640
medium, foetal bovine serum (FBS), penicillin, strep-
tomycin and glutamine were from Sigma (Poole,
Dorset, UK). Dulbecco’s modi¢ed Eagle’s medium
(DMEM-HAT) containing 100 WM hypoxanthine,
0.4 WM aminopterin, 16 WM thymidine and 25 mM
glucose was from Gibco BRL-Life Technologies
(Paisley, UK). Lipid-free foetal calf serum was
from Labtech International (Uck¢eld, Sussex, UK).
Mouse anti-human monoclonal antibodies used to
characterise HUVEC and ECV304 cells were as fol-
lows: anti-CD31, anti-CD62P (AK-4) and anti-
CD106 (51-10C9) from Serotec (Kidllngton, Oxford,
UK), anti-CD54 (HA58) from Pharmingen (Cowley,
Oxford, UK), MOPC-21 from Sigma (Poole, Dorset,
UK); anti MHC-1 (W6/32) was a gift from Dr G.W.
Butcher (Babraham Institute). Mouse anti-human
monoclonal antibodies from Dako (Ely, Cambridge,
UK) used to characterise puri¢ed human peripheral
blood T lymphocytes and other T cell lines were as
follows: anti-CD2 (MT910), anti-CD3 (UCHT1),
anti-CD4 (MT310), anti-CD8 (DK25) and anti-
CD45 (T29/33). Horseradish peroxidase-conjugated
rat anti-mouse IgG1 (A85-1) and IgG2a (R19-15)
monoclonal antibodies were from Serotec and Phar-
mingen. ‘Red-Out’, murine monoclonal antibody was
from Robbins Scienti¢c Corp. CA, USA. Di¡-Quick
was from Gamidor (Abingdon, Oxford, UK). DPX
mounting medium was from BDH (Poole, Dorset,
UK).
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2.2. Endothelial cells and T cells
Human umbilical vein endothelial cells (HUVECs)
were from TCS Biologicals (Buckingham, UK). Hu-
man umbilical cord ECV304 endothelial cells were a
gift from the late Professor Irving B. Fritz. They
were cultured (passage numbers 149^159) in medium
199 containing 10% (v/v) heat-inactivated FBS, 100
U/ml penicillin, 100 Wg/ml streptomycin and 2 mM L-
glutamine at 37‡C in 5% CO2. Human EA.hy926
endothelial cells [16] were a gift from Dr C.-J.S.
Edgell (University of North Carolina) and were cul-
tured (passage numbers 232^240) in DMEM-HAT
medium containing 10% (v/v) FBS, antibiotics and
glutamine as above. 12U104 cells/ml (ECV304 and
EA.hy926) were seeded into each well of a 24-well
plate (2 cm2/well, Limbro plate) and cultured for 48
h prior to assay. Jurkat (E6.1) (human leukaemic T
cell lymphoblast) and HPB-ALL (human acute lym-
phoblastic leukaemia T cell) cell lines were a gift
from Dr D.R. Alexander (Babraham Institute). Oth-
er human T cell lines: D1.1 was from ATCC (Amer-
ican Type Culture Collection, Manassas, VA, USA),
ACC282 (Jurkat sub-clone: human T cell leukaemia)
was from DSMZ (Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen, Braunschweig, Ger-
many) and MOLT-4 (acute T lymphoblastic leukae-
mia) was from ECACC (European Collection of Cell
Culture, Salisbury, UK). T cell lines were cultured in
RPMI 1640 medium containing 10 (v/v) FBS (5%
FBS for HPB-ALL cells), antibiotics and glutamine
as above.
Human peripheral T lymphocytes were prepared
from freshly-drawn blood from healthy, adult donors
by a method based on the protocol (Sigma) for His-
topaque 1077. Brie£y, platelets were removed by de-
¢brination in roller tubes containing glass beads (2^3
mm diameter), ‘Red-Out’ murine monoclonal was
used to remove erythrocytes, and polymorphonuclear
leukocytes were removed by density gradient centri-
fugation with Histopaque 1077. Lymphocytes were
¢nally resuspended in platelet-poor plasma (collected
plasma that was centrifuged at 3400 rpm for 20 min)
and used for adhesion assays after further washing
within 1 h. The cells were roughly spherical with no
evidence of shape changes, and they were 100% via-
ble as judged by trypan blue exclusion. The purity of
the cell preparations was determined with a Coulter
counter and by cytochemical staining with Di¡-
Quick, and the expression of cell surface markers
was monitored by £ow cytometry with monoclonal
antibodies. The purest preparation contained 91.3%
T lymphocytes, 0.7 þ 0.2% monocytes and 7.5 þ 0.4%
neutrophils, with very low contamination by eryth-
rocytes and platelets. 88% of the cells were positive
for CD3, 47% for CD4 and 34% for CD8. Less than
1% of the cells were positive for CD14 (monocytes)
and less than 4% for CD19 (B cells).
2.3. Surface markers on endothelial and T cells
HUVEC or ECV304 cells were passaged (passage
2^3 for HUVECs and passage 148^157 for ECV304)
and grown to con£uence on coverslips which had
been coated overnight with 1% gelatin at room tem-
perature. Con£uent cell monolayers were stimulated
with 30 nM thrombin for 10 min at 37‡C, or 50^100
ng/ml of TNF-K for 4^6 or 16^18 h. After stimula-
tion, the monolayers were washed in phosphate-bu¡-
ered saline (PBS) and ¢xed in ice-cold 100% acetone
for 3^5 min. Acetone was removed by washing with
PBS, and the monolayers were incubated with mouse
anti-human monoclonal antibodies (primary anti-
body) in PBS containing 1% human serum albumin
(PBS^HSA) for 1 h at room temperature. After re-
moval of unbound primary antibody by washing,
monolayers were incubated with a second monoclo-
nal antibody, horseradish peroxidase-conjugated
rat anti-mouse IgG1 or IgG2a (1:100 dilution), in
PBS^HSA for 1 h at room temperature. The mono-
layers were washed, and DAB was then added to
develop the desired intensity of staining. The cover-
slips were counterstained with hematoxylin and
mounted with DPX. For positive and negative con-
trols, MHC-1 and MOPC-21 were used as primary
antibodies under identical conditions to those de-
scribed above.
Expression of cell surface markers on peripheral
blood T lymphocytes and T cell lines was monitored
by £ow cytometry with £uorescent conjugated mono-
clonal antibodies. Prior to labelling, the cells were
washed twice in cold PBS^HSA and labelled with
appropriate FITC and RPE antibodies at room tem-
perature in the dark for 15 min. Samples were then
¢xed with 1% formaldehyde and analysed using a
standard Argon laser source on a Beckman Coulter
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Epics Elite £ow cytometer. Analysis regions were set
using matched isotype controls.
2.4. Prothrombinase assay
The production of thrombin (prothrombinase ac-
tivity) was used as an indirect assay for PS exposed
on cell surfaces. Endothelial cells were treated with
agonist for 10 min in medium 199 without phenol
red containing 0.25% HSA (medium A) and the
supernatant medium (¢rst supernatant: S1) was re-
moved. Clotting factors and prothrombin were
added to it, and aliquots withdrawn over a period
of 12 min to determine the prothrombinase activity
of microvesicles released from the cells as described
previously [17]. The ¢nal concentrations of reagents
in the assay were 0.036 U/ml factor Xa, 1.09 nM
factor Va, 0.36 WM prothrombin, 1.8 mM Ca2
and 150 WM S-2238. Immediately after removing
the ¢rst supernatant, the cells were washed and fresh
medium A was added followed by clotting factors
and prothrombin. Aliquots were withdrawn (second
supernatant: S2) over 12 min to determine the
thrombin generated as a measure of the prothrombi-
nase activity of the treated cells and microvesicles
additionally released from the cells.
Flow cytometry with FITC^annexin V was not
used to determine the surface exposure of PS on
endothelial cells because it requires the use of pro-
teolytic enzymes or mechanical scraping to detach
the cells from the culture dish. In varying degrees,
these treatments might activate the cells (leading to
surface exposure of PS), and/or damage the plasma
membrane (making PS accessible in the inner mono-
layer).
2.5. Cytosolic Ca2+
ECV304 and EA.hy926 cells were plated on 22 mm
diameter coverslips for Ca2 imaging in an inverted
£uorescent Nikon Diaphot microscope. The cells
were incubated with 5 WM £uo-3 AM for 30 min
at 37‡C in 5% CO2 in medium 199 without phenol
red (medium B) supplemented with 10% heat-inacti-
vated foetal calf serum. They were then gently
washed three times in pre-warmed medium A to re-
move excess £uo-3. The coverslip was placed in a
thermostatically controlled bath on the microscope
stage, and the cells were illuminated with a xenon
UV lamp (excitation 490 nm). Emitted light at 520
nm was collected via an attached image intensi¢ed
charge-coupled device camera using a MagiCal sys-
tem and TARDIS software (Joyce-Loebel). Although
great care was taken to avoid directly projecting me-
dia onto the cells, the loading procedure could lead
to a rise in cytosolic Ca2 resulting from mechanical
sheer stress on the cells whilst washing and manipu-
lating the coverslip. This was particularly apparent in
preliminary experiments with fura-2. After placing
the cells on the microscope stage, they were therefore
left for 10 min to allow cytosolic Ca2 to return to
basal levels after the loading procedure. For image
acquisition, eight images were acquired that were
averaged to produce a single image every 0.9 s.
This procedure reduced background noise generated
from stray light. Images were analysed as a self-ratio
(F/F0) (£uorescent intensity at time t/£uorescent in-
tensity at zero time) to monitor changes in the con-
centration of cytosolic Ca2.
2.6. Adhesion of T cells
T cells and endothelial cells were cultured, the T
cells labelled with CMFDA, and the adhesion of T
cells to monolayers of endothelial cells was assessed
qualitatively (by £uorescence microscopy) and quan-
titatively (by spectro£uorometry) as previously de-
scribed [17]. After treatment with thrombin, or an-
nexin V followed by thrombin, the endothelial cells
were washed prior to the addition of Jurkat cells.
2.7. LDL and oxidised LDL (ox-LDL)
LDLs were prepared from healthy volunteers, and
minimally oxidised or fully oxidised, as described
previously [18]. LDL preparations were stored under
nitrogen and used within 3^4 days of preparation.
Control experiments with the ¢nal dialysate showed
that diethylenetriaminepenta-acetic acid, used to pro-
tect LDL against oxidation during LDL preparation,
did not induce a prothrombinase response in
ECV304 cells.
2.8. Flow cytometry
HUVEC or ECV304 cells were grown to con£uent
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monolayers in 25 cm2 £asks for 48 h, washed in pre-
warmed medium B, and incubated with 30 nM
thrombin in medium A for 10 min. Jurkat cells
were washed in medium B to remove serum and
suspended in medium A at a density of 4U106
cells/ml. The endothelial cells were washed to remove
thrombin; Jurkat cells were then added at 20U106
per £ask and incubated for 10 or 20 min at 37‡C.
Non-adherent Jurkat cells were removed in washes of
RPMI 1640 culture medium containing 10% heat-in-
activated foetal calf serum and 2 mM Ca2 (medium
C). Adherent Jurkat cells were detached by treatment
with 5 ml of Hank’s balanced salt solution contain-
ing 1 mM EDTA for a few seconds, and resuspended
in medium C. Collected Jurkat cells were washed
twice in cold PBS, and resuspended in ‘binding bu¡-
er’ (Pharmingen) at a density of 1^5U106 cells/ml.
5 Wl of annexin V^FITC solution and 10 Wl of PI
(50 Wg/ml) were added to 100 Wl of cell suspension.
The cells were gently mixed and incubated for 15 min
at room temperature in the dark. Binding was termi-
nated by adding 400 Wl binding bu¡er, and the cells
were then analysed immediately by £ow cytometry
on a FACSCalibur (Becton Dickinson, San Jose,
CA, USA). Each data ¢le of 10 000 events was ana-
lysed with CELLQuest software. Annexin V^FITC
and PI were detected through 530/30 and 585/42
band pass ¢lters, respectively. For pretreatment
with unlabelled annexin V, collected Jurkat cells
were washed twice in cold PBS, resuspended in bind-
ing bu¡er at a density of 2^10U106 cells/ml, and 50
Wl of cell suspension was added to 50 Wl of annexin V
solution (1 mg/ml; recombinant or chicken annexin
V) containing 2^4 mM Ca2. After incubation for
15 min at room temperature, annexin V^FITC and
PI were added as above and the incubation was con-
tinued for a further 15 min at room temperature in
the dark prior to terminating the binding.
3. Results
3.1. Exposure of PS on thrombin-treated HUVECs
and PS-dependent adhesion of Jurkat cells
The development of a procoagulant response (pro-
thrombinase activity), which provides an indirect as-
C
Fig. 1. Procoagulant response of HUVECs treated with throm-
bin. HUVECs were treated with 30 nM thrombin for 10 min at
37‡C with or without 1100 nM puri¢ed chicken annexin V, and
the supernatant medium (¢rst supernatant: S1) was then re-
moved. Clotting factors and prothrombin were added to it, and
aliquots withdrawn over a period of 12 min to determine the
thrombin produced by the prothrombinase activity of microves-
icles that had been released from the cells. Immediately after
removing the ¢rst supernatant, the cells were washed and fresh
HSA medium was added followed by clotting factors and pro-
thrombin. Aliquots were withdrawn (second supernatant: S2)
over 12 min to determine the thrombin generated. This subse-
quent procoagulant response represented the prothrombinase
activity of the treated cell monolayers and additionally released
microvesicles. a, control-S1 (¢rst supernatant): untreated cells.
b, Thr-S1 (¢rst supernatant): thrombin-treated cells. E, con-
trol-S2 (second supernatant): untreated cells. F, Thr-S2 (second
supernatant): thrombin-treated cells. R, AnV/Thr-S1 (¢rst
supernatant): annexin V-pretreated, thrombin-treated cells. 8,
AnV/Thr-S2 (second supernatant): annexin V-pretreated,
thrombin-treated cells. The data points are mean values þ
S.E.M. for three independent experiments, in each of which
three replicate measurements were made of the thrombin gener-
ated at each time point. (Thr-S1 refers to thrombin generated
additionally to the 30 nM thrombin already present in the ¢rst
supernatant).
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say for exposed PS, has previously been shown to be
highly speci¢c for PS [19,20]. HUVECs were treated
with 30 nM thrombin for 10 min and the supernatant
medium (¢rst supernatant: S1) was removed to de-
termine the prothrombinase activity (thrombin pro-
duction) of microvesicles released from the cells. The
cells were then washed, fresh medium was added
followed by clotting factors and prothrombin, and
aliquots were withdrawn (second supernatant: S2)
to determine the prothrombinase activity of the
treated cells and microvesicles additionally released
from the cells.
The prothrombinase activity of microvesicles in
the ¢rst supernatant from control cells that were in-
cubated without thrombin was very low (Fig. 1: con-
trol-S1). The addition of clotting factors and pro-
thrombin to monolayers of endothelial cells results
in the formation of thrombin [21], and higher levels
of thrombin were consequently observed in the sec-
ond supernatant on subsequently incubating the con-
trol cells with clotting factors and prothrombin (Fig.
1: control-S2). Procoagulant microvesicles were re-
leased into the ¢rst supernatant from the thrombin-
treated cells (Fig. 1: Thr-S1). The highest prothrom-
binase activity was observed with the second super-
natants taken from thrombin-treated cells that were
subsequently incubated with clotting factors and pro-
thrombin (Fig. 1: Thr-S2).
Annexin V binds with high speci¢city to PS via a
Ca2-bridging mechanism, and this property has
been employed in many studies as a probe for mon-
itoring the surface exposure of PS. The addition of
annexin V (1100 nM) 10 min before adding thrombin
to HUVECs resulted in a lower prothrombinase ac-
tivity of the ¢rst supernatant, con¢rming the pres-
ence of PS on the surface of the microvesicles (Fig.
1: AnV/Thr-S1). Since this procedure also decreased
the procoagulant response when the thrombin-
treated cells were incubated with clotting factors
and prothrombin (Fig. 1: AnV/Thr-S2), surface PS
must have been present on the surface of the cells
where it bound annexin V. The bound annexin V
then inhibited the formation of thrombin when the
cells were incubated with clotting factors and pro-
thrombin.
Jurkat T cells were labelled with the cytoplasmic
£uorophore, 5-chloromethyl£uorescein, and incu-
bated at 37‡C for 20 min with a monolayer of HU-
VECs that had previously been incubated with 30
nM thrombin for 10 min. Very few Jurkat cells ad-
hered to untreated HUVECs (Fig. 2A) by compari-
son with the number that adhered to the thrombin-
Fig. 2. Fluorescent micrographs of Jurkat cells, labelled with CMFDA, adhering to monolayers of HUVECs. The two cell types were
treated as described in Section 2. (A) untreated HUVECs, (B) HUVECs treated with 30 nM thrombin, (C) HUVECs pre-incubated
with puri¢ed chicken annexin V (1100 nM) in medium A for 10 min in 5% CO2 before adding thrombin, (D) thrombin-treated HU-
VEC cells incubated with Jurkat cells in medium A containing 2.5 mM EGTA. (A^D) are at the same magni¢cation: bar = 130 Wm.
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treated endothelial cells (Fig. 2B). Jurkat cell adhe-
sion to HUVECs that had been pre-incubated with
1100 nM chicken annexin V before the addition of
thrombin was greatly decreased (Fig. 2C), showing
that the observed adhesion was PS-dependent.
3.2. PS-dependent adhesion of Jurkat cells to
agonist-treated endothelial cell lines
Cell lines, which behave more reproducibly than
cells from umbilical veins, are widely used as models
for endothelial cells. ECV304 and EA.hy926 human
cell lines were therefore employed for quantitative
experiments on the PS-dependent adhesion of Jurkat
cells to thrombin-treated endothelial cells.
The ECV304 cells used were shown previously to
stain positively for Ulex europaeus agglutinin I, a
marker for vascular endothelium in human tissues,
but they contained very few Weibel-Palade bodies
[17]. In the present work, we compared the expres-
sion of four endothelial cell surface markers on
ECV304 cells with their expression on HUVECs. Un-
treated, thrombin-stimulated and TNF-K-stimulated
ECV304 cells were all positive for the immunoglob-
ulin superfamily adhesion molecules, ICAM-1
(CD54) and VCAM-1 (CD106), but these markers
were strongly expressed on HUVECs only after stim-
ulation with TNF-K. PECAM-1 (CD31) was not ex-
pressed on untreated, thrombin-stimulated or TNF-
K-stimulated ECV304 cells, but was present on HU-
VECs that were stimulated with TNF-K, while P-se-
lectin (CD62P) was expressed weakly on both cell
types. It is thus apparent that ECV304 cells resemble
but are not identical with HUVECs.
The procoagulant responses of ECV304 and
EA.hy926 cells to thrombin, ionophore A23187 and
BHQ are shown in Table 1. Each of these agonists
increases cytosolic Ca2. Thrombin, acting via Ins-
(1,4,5)P3 primarily mobilises Ca2 from intracellular
stores [22], A23187 primarily allows the entry of ex-
ternal Ca2 [23], while BHQ inhibits the 97 kDa iso-
form of the Ca2-ATPase of the endoplasmic retic-
Table 2
E¡ect of annexin V on the procoagulant response of endothelial cells treated with BHQ
Protocol Thrombin generated (nM)
ECV304 cells EA.hy926 cells
Second supernatant (S2): BHQ-treated cells 45.8 þ 10.3 (n = 3) 23.9 þ 12.3 (n = 4)
Second supernatant (S2): annexin V-pretreated, BHQ-treated cells 14.0 þ 7.0 (n = 3) (n = 4)a
Endothelial cells were treated with 50/100 WM BHQ (ECV304/EA.hy926 cells), without or with 1100 nM puri¢ed chicken annexin V
as described previously [17], to generate the second supernatants (S2) as described in Section 2. Mean values þ S.E.M. of the addition-
al nM thrombin generated at the 7 min time points in the prothrombinase assays for the treated cells, relative to the corresponding
control values for the untreated cells, are shown. The data are from three or more independent experiments, in each of which three
replicate measurements were made.
aProthrombinase activity not signi¢cantly di¡erent from corresponding control, untreated cells.
Table 1
Procoagulant response of endothelial cells treated with thrombin, ionophore A23187 and BHQ
Protocol Cell line Agonists (nM thrombin generated)
Thrombin A23187 BHQ
First supernatant (S1) from treated cells ECV304 2.1 þ 1.4 (n = 3) 20.6 þ 4.2 (n = 5) 0.3 þ 0.1 (n = 3)
EA.hy926 4.1 þ 1.5 (n = 3) 15.0 þ 2.4 (n = 5) 0.2 þ 0.2 (n = 4)
Second supernatant (S2) from treated cells ECV304 17.9 þ 2.0 (n = 3) 69.5 þ 7.6 (n = 5) 45.8 þ 10.3 (n = 3)
EA.hy926 17.8 þ 7.0 (n = 3) 80.6 þ 7.1 (n = 5) 23.9 þ 12.3 (n = 4)
Cells were treated with 30 nM thrombin, 10 Wg/ml A23187 or 50/100 WM BHQ (ECV304/EA.hy926 cells) for 10 min at 37‡C to gener-
ate the ¢rst and second supernatants (S1 and S2) as described in Section 2. Mean values þ S.E.M. are given for the additional nM
thrombin generated at the 7 min time points in prothrombinase assays for the treated cells, relative to the corresponding control val-
ues for the untreated cells, are from the number of independent experiments shown in each of which three replicate measurements
were made.
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ulum and inhibits the re-uptake into internal stores
of leaked Ca2 [24]. As the treated cells very rarely
became permeable to trypan blue, the procoagulant
responses induced by the agonists were not the result
of cell lysis. The high prothrombinase activities of
the ¢rst supernatants (S1) from cells treated with
A23187 showed that more PS-bearing microvesicles
were immediately released into the medium by the
ionophore than by the other two agonists. Very
few procoagulant microvesicles were released into
the ¢rst supernatants by BHQ. There was neverthe-
less a marked procoagulant response when clotting
factors and prothrombin were added to BHQ-treated
cells after removing the ¢rst supernatant (Table 1).
This response (S2), which represents the prothrombi-
nase activity of the treated cells themselves, and mi-
crovesicles additionally released from the cells, was
inhibited by adding annexin V (1100 nM) to ECV304
cells 10 min before adding BHQ (Table 2). PS was
therefore present on the surface of BHQ-treated cells
where it bound the added annexin.
Jurkat cells adhered to ECV304 cells treated with
thrombin, ionophore A23187 or BHQ. With all three
agonists, the number of adhering Jurkat cells was
decreased by pretreating the endothelial cells with
1100 nM annexin V prior to adding the agonist,
showing that the adhesion was PS-dependent (Table
3). A23187 was the least e¡ective of the three ago-
nists in inducing Jurkat cell adhesion. This was pre-
sumably because a high proportion of the PS that
was exposed on the surface of the cells treated with
A23187 was immediately released from the cells into
the medium in microvesicular form, as shown in Ta-
ble 1. Comparable observations were made with
EA.hy926 endothelial cells treated with thrombin,
A23187 or BHQ although, in each case, the number
of Jurkat cells adhering to the treated EA.hy926 cells
Fig. 3. Procoagulant responses of ECV304 cells treated with
LDL. ECV304 cells were passaged and grown to con£uence
(24-well plate) for 46 h in medium 199 containing 10% regular,
heated foetal calf serum as described in Section 2. The culture
medium was removed, and the cells incubated at 37‡C for 2 h
in fresh medium 199 containing 10% heated, lipid-free foetal
calf serum, and 50 Wg/ml of LDL (prepared as described in the
text). The cell monolayers were washed prior to assays for pro-
thrombinase activity. b, no agonist (lipid-free foetal calf se-
rum). R, n-LDL. O, n-LDL prepared from plasma containing
0.05 mg/ml of added K-tocopherol LDL. 8, m-LDL. F, ox-
LDL. The data points are mean values of three replicate mea-
surements.
Table 3
Adhesion of Jurkat T cells to ECV304 cells treated with thrombin, A23187 and BHQ
Protocol Adherent Jurkat cells (U1033) (per well)
Thrombin 30 nM A23187 10 Wg/ml BHQ 100 WM
No agonist 59 þ 7 (n = 7) 38 þ 7 (n = 4) 38 þ 7 (n = 4)
Agonist treatment 228 þ 10 (n = 7) 48 þ 20 (n = 3) 163 þ 10 (n = 6)
Annexin V pretreatment followed by agonist treatment 84 þ 10 (n = 7) 18 þ 9 (n = 3) 87 þ 20 (n = 6)
ECV304 cells were treated with agonist for 10 min at 37‡C with or without 1100 nM puri¢ed chicken annexin V. Jurkat cells were
cultured, labelled with CMFDA and their adhesion to monolayers of ECV304 cells assessed spectro£uorometrically as previously de-
scribed [17]. Mean values are shown þ S.E.M. for n separate experiments (each of which was done in duplicate).
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was approximately an order of magnitude less than
to agonist-treated ECV304 cells. However, annexin V
pretreatment was more e¡ective with EA.hy926 cells
than with ECV304 cells in inhibiting Jurkat cell ad-
hesion.
3.3. Adhesion of Jurkat T cells to ECV304 cells
treated with ox-LDL
Several publications, reviewed in [25], have indi-
cated that ox-LDL may contribute to the rolling of
leukocytes on the endothelium. Recently, treatment
of HUVECs with ox-LDL, but not native LDL (n-
LDL), for 5 min or 24 h was found to increase intra-
cellular Ca2 and a¡ect cytoskeletal actin in HU-
VECs [26], while in platelets, ox-LDL (but not n-
LDL) increases the level of intracellular calcium by
directly inhibiting the plasma membrane Ca2-ATP-
ase [27].
In view of these reports, we have investigated
whether ox-LDL induces a procoagulant response
in cultured endothelial cells, indicative of the surface
exposure of PS, and whether this leads to a PS-de-
pendent adhesion of Jurkat T cells. ECV304 cells
were incubated for di¡erent lengths of time at 37‡C
with 50 Wg/ml of LDL or modi¢ed LDL, with or
without annexin V (1100 nM), in culture medium
199 containing 10% lipid-free foetal calf serum. After
washing the cells, the prothrombinase activity of the
second supernatant (S2) was determined. Treatment
of ECV304 cells with extensively ox-LDL (50 Wg/ml)
for 10 min was without e¡ect on the prothrombinase
activity whereas, after 11 and 24 h of incubation,
prothrombinase activity was induced equally by
both n-LDL and ox-LDL. With 2 h of incubation,
increasing procoagulant responses were observed
with cells that were treated with n-LDL, mildly ox-
LDL (m-LDL) and ox-LDL (Fig. 3). Similar data
were obtained with 100 Wg/ml of LDL preparations
(not shown). As might be anticipated, the addition of
K-tocopherol (0.05 mg/ml) to plasma prior to isola-
tion of the LDL decreased the ability of n-LDL to
induce a procoagulant response (Fig. 3). None of the
cells treated with preparations of LDL became per-
meable to trypan blue. Their procoagulant activity in
the prothrombinase assay was therefore not the re-
sult of cell lysis.
Compared with control ECV304 cells, there was
an increase in the number of Jurkat cells adhering
to ECV304 cells that had been incubated with ox-
LDL, and a larger increase with m-LDL. However,
neither of these increases in Jurkat cell adhesion re-
Fig. 4. Kinetics of changes in the £uorescence self-ratio F/F0
for EGTA-pretreated cells. ECV304 cells were pre-incubated at
37‡C for 10 min in medium A (1.8 mM Ca2) to which 5 mM
EGTA had been added. 5 mM Ca2 was then added, and the
change in (F/F0) for each of the cells assessed with time. Each
trace is representative of the total population of 51 ECV304
cells (broken line) and 41 EA.hy926 cells (solid line) that were
imaged as described in Section 2.
Table 4
Adhesion of Jurkat cells to ECV304 cells incubated with LDL
Protocol Adherent Jurkat cells (U1033)
(per well)
No agonist 2.7
n-LDL 2.9
n-LDL and annexin V 2.3
n-LDL plus K-tocopherol 2.5
n-LDL plus K-tocopherol and
annexin V
2.7
m-LDL 3.8
m-LDL and annexin V 3.8
Ox-LDL 3.2
Ox-LDL and annexin V 3.4
ECV304 cells were passaged and grown to con£uence (24-well
plate) for 46 h in culture medium 199 containing 10% regular,
heated foetal calf serum as described in Section 2. The culture
medium was removed, and the cells incubated at 37‡C for 2 h
in fresh medium 199 containing 10% heated, lipid-free foetal
calf serum, and 50 Wg/ml LDL (prepared as described in the
text), with or without 1100 nM puri¢ed chicken annexin V. The
cell monolayers were washed prior to assays for adhesion.
Mean values are shown for eight determinations (four determi-
nations in each of two experiments).
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sulting from LDL treatment of the ECV304 cells was
inhibited by pretreatment of the endothelial cells
with annexin V (Table 4), indicating that it was not
primarily mediated by PS.
3.4. E¡ects of EGTA and characterisation of Jurkat
cell adhesion
By comparison with the response to thrombin
alone, there was an increase in the number of adher-
ing Jurkat cells when they were added (in the pres-
ence of Ca2) to ECV304 cells which had been
treated simultaneously with 30 nM thrombin and
5 mM EGTA (Table 5). Monolayers of EA.hy926
cells responded similarly. Experiments were under-
taken to determine whether EGTA increased cyto-
solic Ca2 and rendered the endothelial cells pro-
coagulant, thereby resulting in Jurkat cell adhesion.
Cultures of ECV304 cells were incubated with 5 mM
EGTA. When 5 mM Ca2 was subsequently added,
an immediate increase in cytosolic Ca2 was ob-
served with both cell lines (Fig. 4). EA.hy926 cells
responded similarly. An increased procoagulant re-
sponse (supernatant S2) relative to control ECV304
cells was also observed following incubation of
the cells for 10 min in medium A (1.8 mM Ca2)
containing added 1 mM EGTA. This presumably
resulted from an in£ux of Ca2 during the prothrom-
binase assay (Fig. 5). (The relatively high prothrom-
binase activity of the second supernatant (S2) from
the control cells was due to the known formation of
thrombin [21] when clotting factors and prothrombin
are added to monolayers of endothelial cells). Very
few procoagulant vesicles (supernatant S1, assayed in
the presence of 3 mM Ca2) were released from the
EGTA-treated cells (Fig. 5), and control experiments
showed that the low procoagulant activity of super-
natant S1 was not due to inhibition of the prothrom-
binase assay.
By contrast to the above observations, the pres-
ence of 5 mM EGTA markedly inhibited cell^cell
Fig. 5. Procoagulant response of ECV304 endothelial cells
treated with EGTA. Cells were treated with 1 mM EGTA for
10 min at 37‡C, and prothrombinase activities were determined
as described in Section 2. a, ¢rst supernatant: control cells. b,
¢rst supernatant: 1 mM EGTA-treated cells. E, second super-
natant: control cells. W, second supernatant: 1 mM EGTA-
treated cells. The data points are mean values þ S.E.M. for two/
four independent experiments for the ¢rst and second superna-
tants, respectively, in each of which three replicate measure-
ments were made of the thrombin generated at each time point.
Standard errors which were smaller than the symbol points on
the graph are not shown.
Table 5
E¡ects of EGTA on the adhesion of Jurkat cells to ECV304
cells
Protocols Adherent Jurkat cells (U1033)
(per well)
ECV304 cells Jurkat
cells
No agonist ^ 37 þ 20
No agonist EGTA 32 þ 30
Thrombin ^ 127 þ 50
Thrombin and
EGTA
^ 234 þ 20
Thrombin EGTA 56 þ 20
Thrombin and
EGTA
EGTA 36 þ 5
ECV304 cells were treated with 30 nM thrombin, with or with-
out 5 mM EGTA, for 10 min at 37‡C. Jurkat cells were cul-
tured, labelled with CMFDA, and their adhesion in the pres-
ence or absence of 5 mM EGTA to washed monolayers of
ECV304 cells was assessed spectro£uorometrically as previously
described [17]. Mean values are shown þ S.E.M. for three sepa-
rate experiments (each of which was done in duplicate).
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adhesion when Jurkat cells were added to mono-
layers of thrombin-treated ECV304 cells (Table 5).
The adhesion of Jurkat cells to thrombin-treated
HUVECs was similarly inhibited by the presence of
2.5 mM (compare Fig. 2D with Fig. 2B) and 5 mM
EGTA. The adhesion of Jurkat cells to thrombin-
treated endothelial cells is therefore Ca2-dependent.
The ability of Jurkat cells labelled with CMFDA
to adhere to PS-coated glass coverslips, compared
with uncoated coverslips, was investigated by £uores-
cence microscopy. No increased adhesion of the cells
to PS-coated glass was observed, and it appears that
the PS-dependent adhesion to thrombin-treated en-
dothelial cells may involve an essential, ancillary fac-
tor(s) on the endothelial cell surface, or that there are
topological or conformational di¡erences between PS
deposited on glass compared with PS that is exposed
on the surface of endothelial cells.
3.5. Surface exposure of PS following cell^cell
contact
A phospholipid scramblase has been reported to
be constitutively high in Jurkat cells [28]. In our
hands, however, the prothrombinase activity of un-
treated Jurkat cells at a density of 3U105 cells/ml
was negligible, although there was some activity
with higher cell densities (6U105 and 12U105 cells/
ml). We therefore employed £ow cytometry with an-
nexin V^FITC and PI to investigate the e¡ects of
contact with endothelial cells on the surface exposure
of PS on Jurkat cells. In the absence of previous
contact with ECV304 cells, the majority of the Jurkat
cells were not stained by annexin V^FITC and were
impermeable to PI, and they thus appeared in the
lower left quadrant of Fig. 6a. Surface PS was
present only on a few PI-impermeable cells (positive
Fig. 6. Exposure of surface PS on Jurkat cells after adhesion to ECV304 cells. Jurkat cells were prepared for £ow cytometry and
stained with annexin V^FITC and PI as described in Section 2. (a) Control Jurkat cells (treated with 1 mM EDTA), (b) Jurkat cells
that had adhered to thrombin-treated (30 nM) ECV304 cells for 10 min at 37‡C, and were then detached in 1 mM EDTA, (c) and
(d) Jurkat cells as in (b) but which were pretreated with (unlabelled) recombinant annexin V, or unlabelled puri¢ed, chicken annexin
V, respectively, prior to £ow cytometry. (a) and (b) are representative of 10 separate experiments, while (c) and (d) are representative
of two and four experiments, respectively.
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staining with FITC; lower right quadrant of Fig. 6a).
When Jurkat cells were allowed to adhere to throm-
bin-treated ECV304 cells for 10 min and then de-
tached by treatment with 1 mM EDTA for a few
seconds (which did not release any ECV304 cells
from the endothelial monolayer), there was an in-
creased number of cells with PS on the surface which
still excluded PI (lower right quadrant of Fig. 6b).
Binding of annexin V^FITC to this population of
cells was prevented by pretreating the detached Jur-
kat cells with (unlabelled) recombinant (Fig. 6c) or
with puri¢ed chicken annexin V (Fig. 6d) prior to
£ow cytometry. Hence it is apparent that close ap-
position of the Jurkat cells and ECV304 cells resulted
in surface exposure of PS on the T cells. Such an
exposure of PS on Jurkat cells may actually be re-
quired for adhesion. Thus, whereas the adherent Jur-
kat cells exhibited an increased exposure of PS on the
surface, £ow cytometry in 10 separate experiments
showed that the level of surface PS on the population
of PI-impermeable Jurkat cells that failed to adhere
to the thrombin-treated ECV304 cells in 10 min was
no greater than on Jurkat cells that had not been in
contact with the endothelial cells.
3.6. Peripheral blood T cells and T cell lines
In three separate experiments, it was found that,
unlike Jurkat cells, the number of peripheral blood T
cells that adhered to ECV304 endothelial cells was
not increased by the exposure of PS on the endothe-
lial cell surface induced by thrombin.
In view of this, we have investigated a number of
T cell lines for comparison with Jurkat cells. As with
the Jurkat cells, treatment of ECV304 cells with
thrombin increased the number of adhering HPB-
ALL and MOLT-4 T cells. Both of these cells lines
were double-positive for CD4 and CD8, while Jurkat
E6.1 cells were strongly positive for CD8 and weakly
positive for CD4 (Table 6). Annexin V inhibited the
increase by varying extents: 90% with Jurkat E6.1
cells, 67% with HPB-ALL cells and 22% with
MOLT-4 cells (Table 6). Although the number of
adhering single-positive ACC282 cells (CD4/
CD83) was markedly increased by the thrombin
treatment, the increase was minimally inhibited
(14%) by pretreatment of ECV304 cells with annexin
V (1100 nM, 10 min). Adhesion of double-negative
(CD43/CD83) D1.1 cells to ECV304 endothelial cells
was not enhanced by treating the endothelial cells
with thrombin (30 nM, 10 min). These ¢ndings are
generally, but not completely, consistent with the
possibility that adhesion to PS on the surface of
thrombin-treated endothelial cells may be a feature
of T cells that express both CD4 and CD8.
4. Discussion
PS that is exposed on the cell surface is known to
Table 6
Adhesion of T cell lines to ECV304 cells treated with thrombin
Protocol Cell line
Jurkat E6.1 HPB-ALL MOLT-4 ACC282 D1.1
Adherent cells (U1033) (per well)
No agonist 68 þ 6 140 þ 4 60 þ 5 79 þ 20 244 þ 10
Thrombin 228 þ 10 263 þ 10 218 þ 18 197 þ 15 255 þ 20
Annexin V followed by thrombin 84 þ 10 180 þ 8 184 þ 10 180 þ 15 238 þ 19
CD marker Cells bearing marker (%)
CD3 80 87 89 72 86
CD4 7.9 88 40 44 0.6
CD8 98 88 69 0.7 0.1
ECV304 cells were treated with 30 nM thrombin, without or with 1100 nM puri¢ed chicken annexin V as described previously [17].
Cultured T cells were labelled with CMFDA, and their adhesion to monolayers of ECV304 cells was assessed spectro£uorometrically
as previously described [17]. Mean values are shown þ S.E.M. for three separate experiments for all data except for Jurkat E6.1 cells
where the mean values þ S.E.M. are for seven separate experiments (each experiment was done in duplicate). CD markers were as-
sessed by £ow cytometry with monoclonal antibodies.
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mediate various cell^cell interactions. For example,
surface PS on apoptotic lymphocytes and aged eryth-
rocytes mediates their interactions with macrophages
[9,10], and on tumour cells with monocytes [11].
However, although much information has been ob-
tained on the protein-dependent interactions of leu-
kocytes with endothelial cells, little consideration has
been given to the possibility that phospholipids
might also be involved. In initial work, we showed
that human ECV304 cells exhibit a procoagulant re-
sponse on treatment with thrombin, and that Jurkat
T cells adhere to the thrombin-treated cells in a PS-
dependent manner [17]. These experiments raised the
possibility that trauma to endothelial cells which oc-
curs in vivo to expose PS might contribute to the
adhesion of T cells to endothelial cells, since per-
turbed endothelial cells express tissue factor and fac-
tor XII activator on the cell surface which can ini-
tiate the formation of thrombin at the site of
perturbation [29]. This thrombin could induce a local
procoagulant response that might be relevant, for
example, to the formation of arterial microthrombi
on arterial endothelial cells [30]. Local procoagulant
responses in endothelial cells may also occur as a
result of the continued, marked generation of throm-
bin that lasts for at least 2 weeks following balloon
angioplasty of coronary arteries [31]. We have now
further investigated the exposure of PS at cell surfa-
ces, and the PS-dependent adhesion of T cells to
endothelial cells, in experiments with HUVECs,
two endothelial cell lines and peripheral blood lym-
phocytes.
The human ECV304 cell line, which we used as
one of the culture models for human endothelial
cells, was initially reported to be a line of spontane-
ously transformed HUVECs [32]. Very recently, dur-
ing the course of our work, the DSMZ (German
Culture Collection) reported that this cell line has
the same DNA ¢ngerprint as the T-24 cell line (hu-
man bladder carcinoma). DNA ¢ngerprinting and
multiplex PCR analysis by ECACC (European Col-
lection of Cell Cultures) has further shown that
ECV304 and T24/83 cells are derived from the
same source and are fundamentally the same cell
line. It is thought that ECV304 is the false line be-
cause T-24 was established in 1970 compared to 1984
for ECV304. However, ECV304 cells have been used
by many investigators as a model for human endo-
thelial cells in a very large number of studies from
which it is clear that the cells do express endothelial
properties. Following the recent karyotyping analysis
of ECV304 cells, the properties of this cell line have
been reviewed in the context of work on HUVECs
and other primary culture endothelial cells (W. Joan
Abbot: manuscript in preparation). It has been con-
cluded that ECV304 cells express a remarkably ‘en-
dothelial’ phenotype, and that the cells have played
and will continue to play an important role as a
useful working endothelial model.
The surface markers found on ECV304 cells in the
present investigation con¢rm the endothelial nature
of the cells used in our laboratory for the present
work. The other cell line which we have employed,
EA.hy926, is a hybrid derived from HUVECs and a
cell line (A549) from a human lung carcinoma [16].
In our experiments, ECV304 and EA.hy926 cells
showed similar changes in cytosolic Ca2 and pro-
coagulant behaviour in response to thrombin,
A23187, BHQ and EGTA. Furthermore, HUVEC
and ECV304 cells exhibited similar procoagulant re-
sponses to thrombin. Jurkat T cells also adhered in a
PS-dependent manner to agonist-treated HUVEC,
ECV304 and EA.hy926 cells. These several ¢ndings
indicate that the behaviour of ECV304 cells reported
here is typical of endothelial cells.
Treatment of ECV304 and EA.hy926 cells with
5 mM EGTA, followed by a return to normal me-
dium, resulted in an in£ux of Ca2 and an increase in
adhering Jurkat cells. This entry of external Ca2 is
consistent with the sustained Ca2 inward current
found when the Ca2 pools of mast cells were de-
pleted by treating the cells with EGTA [33], and with
a considerable increase in cytosolic Ca2 seen in Jur-
kat cells when extracellular Ca2 was complexed with
excess EGTA, followed by a subsequent re-addition
of Ca2 [34].
Ox-LDL is present in extracts of human athero-
sclerotic lesions [35], and it has been shown to in-
crease cytoplasmic Ca2 in endothelial cells [26]. We
therefore investigated the potential ability of ox-LDL
to induce the surface exposure of PS on endothelial
cells and the PS-dependent adhesion of lymphocytes.
Ox-LDL is cytotoxic to a number of cell types, in-
cluding endothelial cells, and it has been suggested
that lesion prone areas may be more sensitive to the
toxicity of ox-LDL than quiescent cells [36]. Never-
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theless, the exposure of PS on the surface of ECV304
cells treated with oxidised preparations of LDL for 2
h in our experiments (Table 4) was not accompanied
by permeability to trypan blue. We were encouraged
to investigate the possibility that ox-LDL might in-
duce a PS-dependent adhesion to T cells by the ob-
servation that treatment of endothelial cells with ox-
LDL increased the adhesion of U937 monocyte-like
cells, without involving P-selectin or E-selectin [37].
An enzymatically degraded but non-oxidised form of
LDL (E-LDL) has also been shown to promote the
adhesion of T lymphocytes to monolayers of endo-
thelial cells [38]. However, although increasing pro-
coagulant responses were observed with ECV304
cells on treatment with n-LDL, m-LDL and ox-
LDL, and there was an increase in the number of
Jurkat cells adhering to the m-LDL- and ox-LDL-
treated cells, the increase in adhesion was not pri-
marily PS-dependent.
The interaction of exposed PS on one cell with a
receptor for PS on a di¡erent cell mediates the rec-
ognition of apoptotic lymphocytes by macrophages
[39] and of neoplastic cells by monocytes [11]. Rela-
tively non-speci¢c, homotypic adhesion, involving
exposed PS on two apposed surfaces, can also facil-
itate adhesion in the presence of Ca2. Although
hydrated bilayers of phospholipid normally repel
each other strongly as a consequence of hydration
repulsion arising from solvation of the polar head
groups, Ca2 ions interact so strongly with PS on
adjacent bilayers that they displace surface water
and enable the bilayers to achieve direct molecular
contact via PS^Ca2^PS bridges [40]. In our experi-
ments, Jurkat cells were unable to adhere to throm-
bin-treated HUVEC and ECV304 cells in the pres-
ence of EGTA. Taken together with the observation
that the adhesion of Jurkat T cells to thrombin-
treated ECV304 cells resulted in the exposure of PS
on the Jurkat cells, this indicates that adhesion of the
two cell types may involve a Ca2 bridge between PS
on the surface of both cells, rather than being recep-
tor-mediated. Whether su⁄cient PS is exposed on
thrombin-treated cells for such a mechanism is not
clear however since, unlike experiments with eryth-
rocytes, a comparison of the prothrombinase activ-
ities of thrombin-treated and lysed endothelial cells
cannot be used to estimate the fraction of exposed
PS on the treated cells because PS is present on
membrane-bound organelles within lysed endothelial
cells. PS may, in fact, mediate the observed cell^cell
interactions in combination with other factors. This
would be consistent with Jurkat cells being unable to
adhere to PS-coated glass. On the other hand, there
may be topological or conformational di¡erences be-
tween PS deposited on glass compared with PS ex-
posed on endothelial cells.
It should be added that, since 2 mM EGTA for 15
min reverses the exposure of PS on DO11.10 T lym-
phocyte hybridoma cells 6 h after the induction of
apoptosis by anti-CD3 antibody [41], the inability of
Jurkat cells to adhere to thrombin-treated HUVEC
and ECV304 cells in the presence of EGTA might
possibly have resulted from PS returning to the inner
lea£et of the plasma membrane of the treated endo-
thelial cells.
The T cells that adhered to thrombin-treated en-
dothelial cells in the work reported here are all tu-
mour cells. This raises the possibility that, in addi-
tion to the factors already known to be involved in
metastasis [42^45], surface PS may contribute to ad-
hesive interactions between endothelial cells and tu-
mour cells prior to the extravasation of malignant
cells. It is relevant that contact between tumour cells
and endothelial cells results in a rise of intracellular
Ca2 in the endothelial cells which enhances cell^cell
adhesion [46,47] and mediates the transendothelial
migration of tumour cells [47]. Electron microscopy
has shown that vesicles are formed on, and shed
from, endothelial cell ‘sprouts’ under the in£uence
of cells from a mammary tumour, and that these
vesicles have procoagulant activity [48]. Contact
with tumour cells may thus lead to the exposure of
surface PS on endothelial cells, via an increase in
their cytoplasmic Ca2, which could facilitate adhe-
sive interactions with tumour cells. PS^Ca2^PS
bridges may be involved in such interactions since
PS has also been observed on the surface of tumour
cells [11,49]. As our observations indicate that adhe-
sion to PS on the surface of thrombin-treated endo-
thelial cells may be a feature of T cells that express
both CD4 and CD8 antigens, it is also interesting
that pleural dissemination of an invasive thymoma,
accompanied by a marked increase in the number of
CD4/CD8 T cells in peripheral blood, has also
been reported [50].
Our ¢nding that Jurkat T cells, but not peripheral
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blood T cells, adhere in a PS-dependent manner to
thrombin-treated endothelial cells is reminiscent of
work reported by Bernard et al. [51]. They found
that anti-E2 (CD99) monoclonal antibodies induced
the homotypic aggregation of Jurkat cells and CD4/
CD8 human thymocytes. Normal peripheral T cells
did not aggregate. The antibodies in question were
reported previously to cause the exposure of PS on
the surface of Jurkat cells and human thymocytes
[52] but, surprisingly, neither exogenous PS nor anti-
bodies directed against PS inhibited the homotypic
aggregation. Our experiments have yielded rather
similar results since they were generally, but not
completely, consistent with adhesion to PS on the
surface of thrombin-treated endothelial cells being a
feature of double-positive (CD4/CD8) T cells.
Normally, only 2^3% of circulating human T cells
express both CD4 and CD8 antigens. However,
there is evidence for increased numbers of double-
positive CD4/CD8 T cells in the peripheral blood
of patients with infectious diseases. CD4(dim)/
CD8(bright) T cells (cf. Jurkat E6.1 cells, Table 6)
have been identi¢ed cyto£uorometrically in periph-
eral blood from patients with EBV-infectious mono-
nucleosis [53], and from a renal transplant recipient
with a cytomegalovirus infection [54]. 10^12% of
CD4/CD8 T cells have been observed in the pe-
ripheral blood of a patient with pulmonary tubercu-
losis [55], and a very high level of double-positive
CD4/CD8 peripheral T cells (s 40% of all the
lymphoid cells) in a HIV patient has been brie£y
reported [56]. Our observations, albeit made in vitro,
indicate that double-positive CD4/CD8 T cells in
individuals bearing infections may adhere to dam-
aged endothelial cells in a PS-dependent manner.
This may contribute to atherosclerosis since there is
growing evidence that infection is a risk factor [57^
59], and many workers regard atherosclerosis as an
in£ammatory, immunological disease [60,61].
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